Table 3.
Summary of adverse events.
| Toxicity | DAC | DAC + chemo | DAC + CIK | |||
|---|---|---|---|---|---|---|
| Grades 1-2 n (%) |
Grades 3-4 n (%) |
Grades 1-2 n (%) |
Grade 3-4 n (%) |
Grades 1-2 n (%) |
Grades 3-4 n (%) |
|
| Neutrogena | 1 (12.5) | 1 (12.5) | 10 (55.56) | 6 (33.33) | 2 (40) | 1 (20) |
| Nausea | 0 (0) | 0 (0) | 5 (27.78) | 0 (0) | 0 (0) | 0 (0) |
| Fatigue | 0 (0) | 2 (25) | 5 (27.78) | 0 (0) | 2 (40) | 0 (0) |
| Drowsiness | 0 (0) | 1 (12.5) | 2 (11.11) | 0 (0) | 0 (0) | 0 (0) |
| Thrombocytopenia | 0 (0) | 0 (0) | 1 (5.56) | 0 (0) | 0 (0) | 0 (0) |
| Hyperhidrosis | 0 (0) | 0 (0) | 1 (5.56) | 0 (0) | 0 (0) | 0 (0) |
Note. Data is n (%). CIK: cytokine induced killer cells; DAC + chemo: decitabine in combination with chemotherapy; DAC + CIK: decitabine in combination with CIK.